Inflammatory Response — Modulation of Systemic Inflammatory Response in Critically Ill Children After Glutamine Supplementation
Citation(s)
Ali S, Roberts PR Nutrients with immune-modulating effects: what role should they play in the intensive care unit? Curr Opin Anaesthesiol. 2006 Apr;19(2):132-9. Review.
Alpers DH Glutamine: do the data support the cause for glutamine supplementation in humans? Gastroenterology. 2006 Feb;130(2 Suppl 1):S106-16. Review.
Andrews F, Griffiths R Glutamine-enhanced nutrition in the critically ill patient. Hosp Med. 2002 Mar;63(3):144-7. Review.
Andrews FJ, Griffiths RD Glutamine: essential for immune nutrition in the critically ill. Br J Nutr. 2002 Jan;87 Suppl 1:S3-8. Review.
Coëffier M, Déchelotte P The role of glutamine in intensive care unit patients: mechanisms of action and clinical outcome. Nutr Rev. 2005 Feb;63(2):65-9. Review.
De-Souza DA, Greene LJ Intestinal permeability and systemic infections in critically ill patients: effect of glutamine. Crit Care Med. 2005 May;33(5):1125-35. Review.
Griffiths RD, Jones C, Palmer TE Six-month outcome of critically ill patients given glutamine-supplemented parenteral nutrition. Nutrition. 1997 Apr;13(4):295-302.
Griffiths RD Outcome of critically ill patients after supplementation with glutamine. Nutrition. 1997 Jul-Aug;13(7-8):752-4. Review.
Griffiths RD Specialized nutrition support in critically ill patients. Curr Opin Crit Care. 2003 Aug;9(4):249-59. Review.
Jiang H, Chen W, Hu W, Cai B, Liao RJ [The impact of glutamine-enhanced enteral nutrition on clinical outcome of patients with critical illness: a systematic review of randomized controlled trials]. Zhonghua Shao Shang Za Zhi. 2009 Oct;25(5):325-30. Review. Chinese.
Rao XP, Zhu LQ, Lian HH [Protective effects of glutamine on the intestinal mucosal barrier in young rabbits under hemorrhagic shock]. Zhongguo Dang Dai Er Ke Za Zhi. 2006 Feb;8(1):66-70. Chinese.
Singleton KD, Beckey VE, Wischmeyer PE GLUTAMINE PREVENTS ACTIVATION OF NF-kappaB AND STRESS KINASE PATHWAYS, ATTENUATES INFLAMMATORY CYTOKINE RELEASE, AND PREVENTS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) FOLLOWING SEPSIS. Shock. 2005 Dec;24(6):583-9.
Singleton KD, Serkova N, Beckey VE, Wischmeyer PE Glutamine attenuates lung injury and improves survival after sepsis: role of enhanced heat shock protein expression. Crit Care Med. 2005 Jun;33(6):1206-13.
Tian H, Wang KF, Wu TJ [Effect of total parenteral nutrition with supplementation of glutamine on the plasma diamine oxidase activity and D-lactate content in patients with multiple organ dysfunction syndrome]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2006 Oct;18(10):616-8. Chinese.
Tubman TR, Thompson SW, McGuire W Glutamine supplementation to prevent morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001457. Review. Update in: Cochrane Database Syst Rev. 2008;(1):CD001457.
van den Berg A, van Elburg RM, Westerbeek EA, Twisk JW, Fetter WP Glutamine-enriched enteral nutrition in very-low-birth-weight infants and effects on feeding tolerance and infectious morbidity: a randomized controlled trial. Am J Clin Nutr. 2005 Jun;81(6):1397-404.
Yeh CL, Hsu CS, Yeh SL, Lin MT, Chen WJ Dietary glutamine supplementation reduces cellular adhesion molecule expression and tissue myeloperoxidase activity in mice with gut-derived sepsis. Nutrition. 2006 Apr;22(4):408-13. Epub 2006 Feb 3.
Zhou YP, Jiang ZM, Sun YH, Wang XR, Ma EL, Wilmore D The effect of supplemental enteral glutamine on plasma levels, gut function, and outcome in severe burns: a randomized, double-blind, controlled clinical trial. JPEN J Parenter Enteral Nutr. 2003 Jul-Aug;27(4):241-5.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.